Top

International Journal of Colorectal Disease

Published in:

01-06-2010 | Original Article

Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression

Authors: Shin Fujita, Hirokazu Taniguchi, Takashi Yao, Tadakazu Shimoda, Hideki Ueno, Takashi Hirai, Masayuki Ohue

Published in: International Journal of Colorectal Disease | Issue 6/2010

Abstract

Background

The risk factors for liver metastasis from colorectal cancer are still unclear. We therefore evaluated the relationships between various clinicopathological factors, including CD10 expression, liver metastasis, and survival, in patients with colorectal cancer.

Methods

Clinicopathological data for 1,025 patients with stage II or III colorectal cancer who underwent curative surgery in four participating hospitals were collected and evaluated. Three pathologists examined focal dedifferentiation, venous invasion, and CD10 expression without knowledge of the clinical outcome.

Results

Univariate analysis showed that pathological T (pT), pathological N (pN), venous invasion, focal dedifferentiation, and CD10 expression were significantly associated with liver metastasis. Multivariate analysis selected pT, pN, and CD10 expression as significant risk factors for liver metastasis. pT, pN and CD10 were also shown by univariate and multivariate analyses to be significantly associated with disease-free survival. The incidence of liver metastasis was 3% in pN0 patients with CD10-negative or pT2 or pT3 tumors and 28% in pN2 patients with CD10-positive or pT4 tumors.

Conclusions

CD10 expression is a significant risk factor for liver metastasis in patients with colorectal cancer and is correlated with prognosis. Patients with a high risk of liver metastasis can be selected on the basis of pT, pN, and CD10 expression.

Sadahiro S, Suzuki T, Ishikawa K, Yasuda S, Tajima T, Makuuchi H, Saitoh T, Murayama C (2004) Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial. Cancer 100:590–597CrossRefPubMed

Xu J, Zhong Y, Weixin N, Xinyu Q, Yanhan L, Li R, Jianhua W, Zhiping Y, Jiemin C (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583–590CrossRefPubMed

Ono M, Sakamoto M, Ino Y, Moriya Y, Sugihara K, Muto T, Hirohashi S (1996) Cancer cell morphology at the invasive front and expression of cell adhesion-related carbohydrate in the primary lesion of patients with colorecatal carcinoma with liver metastasis. Cancer 78:1179–1186CrossRefPubMed

Fujimoto Y, Nakanishi Y, Sekine S, Yoshimura K, Akasu T, Moriya Y, Shimoda T (2005) CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis Colon Rectum 48:1883–1889CrossRefPubMed

Yao T, Takata M, Tustsumi S, Nishiyama K, Taguchi K, Nagai E, Tsuneyoshi M (2002) Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis. Pathology 34:556–560CrossRefPubMed

Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580PubMed

Nelson RL, Freels S (2004) A systematic review of hepatic artery chemotherapy after hepatic resection of colorectal cancer metastatic to the liver. Dis Colon Rectum 47:739–745CrossRefPubMed

Mocellin S, Pilati P, Lise M, Nitti D (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25:5649–5654CrossRefPubMed

Power DG, Healey-Bird BR, Kemeny NE (2008) Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 7:247–259CrossRefPubMed

10.

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403CrossRefPubMed

11.

Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y (2009) Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 20:1236–1241CrossRefPubMed

12.

Ohji Y, Yao T, Eguchi T, Yamada T, Hirahashi M, Iida M, Tsuneyoshi M (2007) Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep 17:525–530PubMed

13.

Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R (2004) CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 45:460–467CrossRefPubMed

14.

Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM (2004) Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 10:4096–4100CrossRefPubMed

15.

Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE (2004) CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol 17:1251–1258CrossRefPubMed

16.

Tajima Y, Yamazaki K, Nishino N, Morohara K, Yamazaki T, Kaetsu T, Suzuki S, Kawamura M, Kumagai K, Kusano M (2004) Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions. Br J Cancer 1:1342–1348CrossRef

17.

Iwase T, Kushima R, Mukaisho K, Mitsufuji S, Okanoue T, Hattori T (2005) Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract 201:83–91CrossRefPubMed

18.

Kajiyama H, Shibata K, Terauchi M, Morita T, Ino K, Mizutani S, Kikkawa F (2005) Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res 11:1798–1808CrossRefPubMed

19.

Charpin C, Giusiano S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S (2009) Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. Int J Oncol 34:983–993CrossRefPubMed

20.

Bird NC, Mangnall D, Majeed AW (2006) Biology of colorectal liver metastases: a review. J Surg Oncol 94:68–80CrossRefPubMed

21.

Turner RR, Li C, Compton CC (2007) Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res 13:6871s–6876sCrossRefPubMed

22.

Zlobec I, Lugli A (2008) Prognostic and predictive factors in colorectal cancer. J Clin Pathol 61:561–569PubMed

23.

Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M (1989) An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63:539–543CrossRefPubMed

Title: Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression
Authors: Shin Fujita
Hirokazu Taniguchi
Takashi Yao
Tadakazu Shimoda
Hideki Ueno
Takashi Hirai
Masayuki Ohue
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 6/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-010-0913-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Damage control with abdominal vacuum therapy (VAC) to manage perforated diverticulitis with advanced generalized peritonitis—a proof of concept

The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma

Potential role of the steroid receptor pattern in the response of inoperable intra-abdominal desmoid to toremifene after failure of tamoxifen therapy

Chylous ascites secondary to pseudomembranous colitis following ileostomy reversal fashioned for low anterior resection

Oncological outcome after incidental perforation in radical rectal cancer surgery

The benefit of an enhanced recovery programme following elective laparoscopic sigmoid colectomy